A children's bone-and-joint surgery course drew a record 39 participants from 3 countries.
OrthoPediatrics (KIDS) sponsored the 10th Pediatric Orthopedic Surgical Techniques (POST) Course, held September 18–19, 2026, in Memphis, Tennessee. The course achieved a record attendance of 39 participants from 23 institutions across 22 cities and three countries. This educational program, designed for senior residents, fellows, and early-career surgeons, combines expert instruction with hands-on learning and included the debut of a new companion manual.
OrthoPediatrics Sponsors the 10th Pediatric Orthopedic Surgical Techniques Course
OrthoPediatrics Corp. sponsored the 10th Pediatric Orthopedic Surgical Techniques (POST) Course, which had a record attendance of 39 participants from 23 institutions and three countries. The course, held in Memphis, Tennessee, provided comprehensive education and hands-on learning for senior residents, fellows, and early-career surgeons. This sponsorship highlights OrthoPediatrics' commitment to advancing pediatric orthopedic education and improving care for children with orthopedic conditions.
KIDS5867370 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the OrthoPediatrics Corp. KIDS5867370 bond, highlighting its coupon and redemption information. It covers key facts such as issuer, issue date, maturity date, face value, and minimum denomination. The profile also includes the coupon rate, frequency, upcoming payment schedule, and current outstanding amount.
OrthoPediatrics Surpasses 1,000 PNP Tibia Nail Implantations
OrthoPediatrics Corp. (Nasdaq: KIDS) has announced that its Pediatric Nailing Platform (PNP) Tibia System has surpassed 1,000 implantations. This system, specifically designed for pediatric patients, includes a unique 7mm cannulated rigid tibial nail, which allows treatment for patients previously untreatable with adult systems. The rapid adoption highlights OrthoPediatrics' success in addressing a critical need in pediatric orthopedic implant offerings.
More than 1,000 children with broken shinbones have been treated with OrthoPediatrics’ system
OrthoPediatrics (KIDS) announced that its PNP Tibia Nail system has surpassed 1,000 implantations in pediatric patients as of September 22, 2026. This system is designed for pediatric-specific needs, featuring a unique 7mm cannulated rigid tibial nail that allows treatment for patients previously untreatable with adult systems. The company plans a broader European rollout in 2027, expanding on its current availability in five markets.
OrthoPediatrics Corp.(NasdaqGM:KIDS) added to S&P Healthcare Equipment Select Industry Index
OrthoPediatrics Corp. (NasdaqGM: KIDS) has been added to the S&P Healthcare Equipment Select Industry Index. The company specializes in designing, developing, and marketing anatomically appropriate implants and devices for children with orthopedic conditions. This inclusion highlights the company's growing presence and importance in the healthcare equipment sector.
How Orthopediatrics Corp. (KIDS) Affects Rotational Strategy Timing
Orthopediatrics Corp. (NASDAQ: KIDS) is currently exhibiting weak near and mid-term sentiment, despite a strong long-term positive outlook. AI models have identified a mid-channel oscillation pattern and an exceptional short setup with a high risk-reward ratio, targeting a 12.7% downside with 0.3% risk. The article details specific trading strategies for different risk profiles, including long, breakout, and short positions, alongside multi-timeframe signal analysis.
Squadron Capital, 10% owner, sells $6.35m in OrthoPediatrics stock
Squadron Capital LLC, a significant owner of OrthoPediatrics Corp. (NASDAQ:KIDS), sold 302,369 shares totaling approximately $6.35 million to fund other portfolio businesses. This sale occurred as KIDS stock trades near $21.56, with InvestingPro analysis suggesting the stock may be overvalued despite recent strong returns. OrthoPediatrics recently reported a 15% increase in Q2 revenue, exceeding Wall Street forecasts.
Orthopediatrics director Pritzker sells $6.35m in shares
Jennifer N. Pritzker, a director and 10% owner of Orthopediatrics Corp (NASDAQ:KIDS), sold 302,369 shares totaling approximately $6.35 million. The sale, made by Squadron Capital LLC to fund other portfolio businesses, involved shares sold between $21.00 and $21.69. Despite the sale, Ms. Pritzker retains significant indirect beneficial ownership in the company.
ORTHOPEDIATRICS CORP (NASDAQ: KIDS) Director David Pelizzon Sells 22,500 Shares at $23.35 Each
ORTHOPEDIATRICS CORP (NASDAQ: KIDS) Director David Pelizzon sold 22,500 shares of the company's stock at $23.35 per share on September 2, 2026. Following this transaction, Pelizzon's total ownership in KIDS stock is 6,504,133 shares. This sale provides investors with updated insight into his stake and the transaction details.
Squadron Capital LLC sells $525k Orthopediatrics (kids) shares By Investing.com
Squadron Capital LLC, a director and 10% owner of ORTHOPEDIATRICS CORP (NASDAQ:KIDS), recently sold 22,500 shares of common stock for a total of $525,375. The sale, executed on September 2, 2026, occurred at a weighted average price of $23.35 per share, with the stock currently trading below this price at $22.41. This transaction was reportedly undertaken to provide additional capital for Squadron Capital LLC's other portfolio businesses.
OrthoPediatrics Director Jennifer N. Pritzker Sells 22,500 Shares Via Squadron Capital LLC
OrthoPediatrics Corp Director Jennifer N. Pritzker, through Squadron Capital LLC, sold 22,500 shares of the company's common stock on September 2, 2026. The shares were sold at a weighted average price of $23.35, generating capital for Squadron Capital LLC's other portfolio companies. Following the transaction, Squadron Capital LLC indirectly beneficially owns 6,504,133 shares.
Squadron Capital LLC sells $525k Orthopediatrics (kids) shares
Squadron Capital LLC, a significant owner of Orthopediatrics Corp (NASDAQ:KIDS), recently sold 22,500 shares totaling $525,375 to provide capital for other portfolio businesses. This transaction occurred on September 2, 2026, with shares sold at a weighted average price of $23.35, though the stock is currently trading lower at $22.41. Despite the sale and an "overvalued" assessment by InvestingPro, OrthoPediatrics recently reported strong Q2 revenue growth and an increased full-year outlook.
OrthoPediatrics (NASDAQ: KIDS) Activist Stake by Squadron Capital Drops to 25.0% Following Share Sales
Squadron Capital LLC has reduced its activist stake in OrthoPediatrics (NASDAQ: KIDS) to 25.0% through open-market share sales, now holding 6,526,633 common shares. The sales were conducted to raise capital for other portfolio investments, though Jennifer N. Pritzker and David R. Pelizzon remain beneficial owners with stakes exceeding 25.0%. This adjustment in direct holdings was disclosed in an activist Schedule 13D filing, while overall beneficial ownership for key individuals remains above 25%.
Orthopediatrics director Jennifer Pritzker sells $7.76m in shares By Investing.com
Jennifer N. Pritzker, a director and 10% owner of ORTHOPEDIATRICS CORP (NASDAQ:KIDS), recently sold shares totaling $7.76 million. The transactions occurred on August 28, 2026, and September 1, 2026, with prices between $23.04 and $23.1 per share, to provide capital for Squadron Capital LLC's other portfolio businesses. Despite the sale, the stock has seen a 29.5% year-to-date return, though InvestingPro analysis suggests it is currently overvalued.
Squadron Capital, 10% owner, sells $7.76m in OrthoPediatrics Corp stock
Squadron Capital LLC, a 10% owner of OrthoPediatrics Corp (NASDAQ:KIDS), sold 336,831 common shares for approximately $7.76 million between August 28 and September 1, 2026. These sales were made to provide capital for Squadron Capital's other portfolio businesses. Despite the stock showing strong recent returns, InvestingPro analysis indicates KIDS may be overvalued relative to its Fair Value.
Orthopediatrics director Jennifer Pritzker sells $7.76m in shares
Jennifer N. Pritzker, a director and 10% owner of ORTHOPEDIATRICS CORP (NASDAQ:KIDS), recently sold over $7.76 million worth of company common stock in transactions on August 28 and September 1, 2026. These sales were conducted by Squadron Capital LLC to fund other portfolio businesses. Despite the insider sale, the company has seen a 29.5% year-to-date return, and recently reported a 15% increase in second-quarter revenue.
OrthoPediatrics Announces Full Commercial Launch of 3P™ Pediatric Plating Platform® Hip System Following More Than 350 Successful Implantations
OrthoPediatrics Corp. has announced the full commercial launch of its 3P™ Pediatric Plating Platform® Hip System following over 350 successful surgical implantations during its limited launch period. This system is the first in a broader portfolio aimed at advancing trauma and deformity correction in pediatric orthopedics. The company emphasizes the system's innovative implant and instrumentation technologies, providing enhanced fixation and procedural versatility for pediatric orthopedic surgeons nationwide.
Orthopediatrics Corp director Jennifer Pritzker sells $943,302 in shares
Orthopediatrics Corp director and 10% owner Jennifer Pritzker sold 38,300 shares of common stock totaling $943,302 over three days, concluding on August 26, 2026. The sales were made by Squadron Capital LLC to provide capital for its other portfolio businesses. Despite the stock being down over 9% in the past week, it has shown strong year-to-date and six-month returns, though InvestingPro analysis suggests it may be overvalued.
Squadron Capital sells $943k in OrthoPediatrics stock
Squadron Capital LLC, a significant owner of OrthoPediatrics Corp (NASDAQ:KIDS), recently sold approximately $943,302 worth of common stock over three days in late August 2026. These sales, which occurred at prices between $24.28 and $25.75 per share, were conducted to provide capital for other portfolio businesses. The transactions took place amidst stock volatility, as KIDS declined 8.4% in the week of the sales, though it maintained strong year-to-date gains of 35% and had recently reported a 15% increase in second-quarter revenue.
OrthoPediatrics Announces Full Commercial Launch of 3P™ Pediatric Plating Platform® Hip System Following More Than 350 Successful Implantations
OrthoPediatrics Corp. has fully launched its 3P™ Pediatric Plating Platform® Hip System in the U.S. after a successful limited release saw over 350 implantations. This system, designed for pediatric hip trauma and deformity correction, is the first in a new platform aimed at modernizing plating technologies for children. The company anticipates this launch will significantly enhance treatment options for pediatric orthopedic surgeons.
OrthoPediatrics Announces Full Commercial Launch of 3P™ Pediatric Plating Platform® Hip System Following More Than 350 Successful Implantations – Ortho Spine News
OrthoPediatrics has announced the full commercial launch of its 3P™ Pediatric Plating Platform® Hip System in the United States, following a successful limited launch period with over 350 surgical implantations. This system is the first in their Pediatric Plating Platform portfolio and is designed to advance trauma and deformity correction in pediatric orthopedics, offering enhanced fixation options and streamlined workflow. The company aims for this system to establish the foundation for a comprehensive and technologically advanced plating portfolio.
OrthoPediatrics Announces Full Commercial Launch of 3P™ Pediatric Plating Platform® Hip System Following More Than 350 Successful Implantations
OrthoPediatrics Corp. has fully launched its 3P™ Pediatric Plating Platform® Hip System after a successful limited release that saw over 350 implantations. This system, designed to modernize plating with advanced implant and instrumentation technologies, is now widely available to pediatric orthopedic surgeons across the U.S. It represents a significant advancement in trauma and deformity correction and is the first of several planned systems to transform the company's plating portfolio.
OrthoPediatrics Corp. Announces Full U.S. Commercial Launch of 3P™ Pediatric Plating Platform® Hip System
OrthoPediatrics Corp. has announced the full U.S. commercial launch of its 3P™ Pediatric Plating Platform® Hip System, following a successful limited release that included over 350 surgical implantations. This system, designed for pediatric hip trauma and deformity correction, is now widely available to surgeons. The launch marks a significant advancement in pediatric orthopedics and is the first in a series of planned systems for the company's plating portfolio.
After 350 implants, a pediatric hip system is now available across the U.S.
OrthoPediatrics (Nasdaq: KIDS) has fully launched its 3P™ Pediatric Plating Platform® Hip System across the United States after a successful limited launch period with over 350 surgical implantations. This system is designed to treat proximal femur trauma and deformities in infants, children, and adolescents, offering advanced implant and instrumentation technologies. The 3P Hip System is the first of several planned products in the broader Pediatric Plating Platform portfolio, aiming to enhance treatment options for pediatric orthopedic surgeons globally.
OrthoPediatrics Announces Full Commercial Launch of 3P™
OrthoPediatrics Corp. has announced the full commercial launch of its 3P™ Pediatric Plating Platform® Hip System following a successful limited launch with over 350 implantations. This system, designed for trauma and deformity correction, is now available to pediatric orthopedic surgeons across the U.S. It represents the first of several planned systems within the Pediatric Plating Platform, aiming to modernize plating with advanced implant and instrumentation technologies.
OrthoPediatrics (NASDAQ: KIDS) 10% holder plans 700K-share sale
Squadron Capital, a 10% shareholder in OrthoPediatrics (NASDAQ: KIDS), has filed a notice to sell up to 700,000 shares of common stock. This sale, valued at approximately $18.36 million, represents about 10% of Squadron's holdings and is intended to provide capital for its other portfolio businesses. The shares were originally acquired on September 20, 2022, through a purchase involving cash and forgiveness of debt.
OrthoPediatrics (NASDAQ:KIDS) Shares Down 3.7% - Here's What Happened
OrthoPediatrics (NASDAQ:KIDS) saw its shares drop 3.7% to $25.25 in mid-day trading on Friday, with trading volume significantly lower than average. Despite the decline, analyst sentiment remains largely positive, with a consensus "Moderate Buy" rating and an average price target of $26.44. The company recently exceeded quarterly expectations for both earnings per share and revenue.
BTIG Research Issues Positive Forecast for OrthoPediatrics (NASDAQ:KIDS) Stock Price
BTIG Research has raised its price target for OrthoPediatrics (NASDAQ:KIDS) from $24 to $29, maintaining a "buy" rating and indicating a potential upside of 9.43%. This positive outlook aligns with a consensus "Moderate Buy" rating from analysts, as the company recently exceeded quarterly expectations with a narrower loss per share and higher revenue than anticipated. Several other firms have also adjusted their price targets and ratings for OrthoPediatrics, reflecting a generally optimistic sentiment for the medical device company.
OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates
OrthoPediatrics (KIDS) reported a narrower-than-expected Q2 loss of $0.26 per share, beating the Zacks Consensus Estimate of a $0.31 loss, and also surpassed revenue estimates with $70.51 million against a consensus of $68.03 million. Despite outperforming the market year-to-date, the stock currently holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market. Investors are advised to monitor future earnings estimate revisions for further insights.
AIGH Capital Management LLC Takes Position in OrthoPediatrics Corp. $KIDS
AIGH Capital Management LLC has acquired a new position in OrthoPediatrics Corp. (NASDAQ:KIDS), purchasing 269,765 shares valued at approximately $5.16 million, making it their 28th largest holding. OrthoPediatrics recently exceeded analysts' revenue and EPS estimates, reporting $70.51 million in revenue and an adjusted loss of $0.26 per share. Analysts generally maintain a "Moderate Buy" rating for the stock with an average target price of $25.89.
OrthoPediatrics Sees ‘Inflection Point’ as New Products Fuel Record Quarter
OrthoPediatrics (KIDS) reported record revenue and adjusted EBITDA in Q2, with CEO Dave Bailey stating the quarter marked an "inflection point" due to contributions from new products like the 3P Hip System and VerteGlide. The company anticipates continued record performance in H2, driven by strong summer volumes, new product launches, and strategic portfolio expansion including the Veraxis fixation system and growth in specialty bracing. OrthoPediatrics also plans to leverage its strengthened position in Europe and revised operating structures in Latin America to boost international growth and profitability.
OrthoPediatrics Sees ‘Inflection Point’ as New Products Fuel Record Quarter
OrthoPediatrics reported record revenue and adjusted EBITDA in Q2, with CEO Dave Bailey highlighting new "super cycle" products and summer volumes as key drivers. The company anticipates continued growth in the second half of the year, driven by increasing contributions from new hip and spine systems, and expects its specialty bracing business and international markets to further boost performance. OrthoPediatrics is also focusing on capital discipline and strategic partnerships to strengthen its competitive position in pediatric orthopedics.
Wasatch Advisors LP Buys 186,357 Shares of OrthoPediatrics Corp. $KIDS
Wasatch Advisors LP significantly increased its stake in OrthoPediatrics Corp. (NASDAQ:KIDS) by 56.6% in the second quarter, purchasing an additional 186,357 shares. This brings their total holdings to 515,677 shares, representing 2.01% of the company. OrthoPediatrics recently reported better-than-expected earnings, with a smaller loss per share and higher revenue than anticipated, and analysts currently have a "Moderate Buy" rating on the stock.
Understanding the Setup: (KIDS) and Scalable Risk
This article provides an in-depth analysis of Orthopediatrics Corp. (NASDAQ: KIDS), highlighting a potential long-term breakout if current strong sentiment holds. It offers AI-generated signals, institutional trading strategies tailored to different risk profiles, and a multi-timeframe signal analysis to guide investors. Key findings indicate compelling upside potential with no remaining resistance levels above the current price.
Dimensional Fund Advisors LP Has $8.67 Million Stake in OrthoPediatrics Corp. $KIDS
Dimensional Fund Advisors LP reduced its stake in OrthoPediatrics Corp. (NASDAQ:KIDS) by 12.2% in the first quarter, though it still holds 546,626 shares valued at $8.67 million. Institutional investors collectively own 69.05% of the stock. Analysts generally maintain a "Moderate Buy" rating for OrthoPediatrics, with an average price target of $25.89, following the company's recent beat on quarterly earnings and revenue expectations.
Orthopediatrics Corp Q2 2026: Revenue $70.5M, EPS $(0.30) — 10-Q Summary
Orthopediatrics Corp (KIDS) reported its Q2 2026 financial results, with revenue increasing to $70.5 million from $61.1 million year-over-year. The company posted a net loss of $7.16 million and diluted EPS of $(0.30), largely consistent with the previous year. Key growth drivers included Trauma & Deformity products, operational expansion in Europe, Canada, and Brazil, and strong product momentum across its portfolio.
OrthoPediatrics Corp. Reports Second Quarter 2026 Financial Results and Increases 2026 Financial Guidance
OrthoPediatrics Corp. announced strong financial results for the second quarter of 2026, with revenue surpassing $70 million for the first time, marking a 15% year-over-year increase. The company also reported record adjusted EBITDA of $6.8 million and significantly reduced free cash flow usage. Consequently, OrthoPediatrics raised its full-year 2026 revenue guidance to between $265.0 million and $269.0 million, expecting continued growth and aiming for cash-flow breakeven in 2026.
OrthoPediatrics Corp. Stock 12‑Month Price Target Raised to $26.67, Implies 28% Upside
Analysts have raised the 12-month average price target for OrthoPediatrics Corp. stock from $25 to $26.67, with individual forecasts ranging from $22 to $35 per share. This new target implies a potential upside of approximately 28% from the Aug. 4 closing price. The consensus rating among 9 covering analysts remains a "Buy," with 8 recommending a Buy and 1 a Hold.
ORTHOPEDIATRICS CORP : NEEDHAM RAISES TARGET PRICE TO $35 FROM $30
Needham has increased its target price for ORTHOPEDIATRICS CORP (KIDS.O) to $35 from the previous $30. This adjustment indicates a more optimistic outlook by the analyst firm regarding the company's future stock performance. The report was issued by Reuters.
OrthoPediatrics (Nasdaq: KIDS) lifts 2026 guidance after strong Q2 growth
OrthoPediatrics reported record Q2 2026 net revenue of $70.5 million, marking a 15% increase year-over-year, primarily driven by strong growth in Trauma and Deformity products and international sales. The company also achieved a record adjusted EBITDA of $6.8 million and significantly improved free cash flow usage. Consequently, OrthoPediatrics raised its full-year 2026 revenue guidance to between $265.0 million and $269.0 million.
OrthoPediatrics: Q2 Earnings Snapshot
OrthoPediatrics Corp. (KIDS) reported a Q2 loss of $7.2 million, or 30 cents per share, which adjusted to 26 cents per share. The medical device maker posted revenue of $29.5 million for the quarter and expects full-year revenue to be between $125 million and $129 million. This report was generated using data from Zacks Investment Research.
OrthoPediatrics (NASDAQ: KIDS) eyes $265M–$269M 2026 revenue, cash breakeven
OrthoPediatrics Corp. (NASDAQ: KIDS) is projecting 2026 revenue between $265 million and $269 million, alongside an Adjusted EBITDA of approximately $25 million and roughly breakeven free cash flow. This outlook is detailed in an investor update that also highlights the company's focus on the $6.2 billion global pediatric orthopedic market, its broad product portfolio, and continuous innovation. Despite consistent revenue growth, OrthoPediatrics has continued to post net losses, with diluted EPS at $(1.69) in 2025.
Nearly 46,000 children helped as OrthoPediatrics revenue hits $70.5M
OrthoPediatrics (Nasdaq: KIDS) reported record Q2 2026 revenue of $70.5 million, a 15% year-over-year increase, driven by strong growth in U.S. and international markets, particularly in its Trauma & Deformity segment. The company helped nearly 46,000 children and achieved a record adjusted EBITDA of $6.8 million, leading to an increased full-year 2026 revenue guidance of $265-269 million. Despite a decline in Scoliosis revenue and a net loss of $7.2 million, OrthoPediatrics improved its free cash flow usage significantly and announced a new exclusive distribution agreement with OSSIO for bio-integrative fixation technology.
OrthoPediatrics Corp. Reports Second Quarter 2026 Financial Results and Increases 2026 Financial Guidance
OrthoPediatrics Corp. announced strong financial results for the second quarter of 2026, with record total revenue of $70.5 million, marking a 15% year-over-year increase, and record adjusted EBITDA of $6.8 million. The company helped nearly 46,000 children and significantly reduced free cash flow usage. Consequently, OrthoPediatrics raised its full-year 2026 revenue guidance to between $265.0 million and $269.0 million.
The Technical Signals Behind (KIDS) That Institutions Follow
This article from Stock Traders Daily discusses the technical signals for Orthopediatrics Corp. (NASDAQ: KIDS) that institutions follow. It highlights strong near-term sentiment with neutral mid and long-term outlooks, noting compelling upside potential due to a lack of resistance levels above the current price. The article also outlines AI-generated institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
OrthoPediatrics Number of Employees 2026 | Employee Count & Headcount Data
OrthoPediatrics Corp. (NASDAQ: KIDS) has approximately 606 employees worldwide as of March 2026, marking a 13.6% growth from 2023. The company is actively hiring, with 45 active job postings in 2026, an 11.8% increase from 2025. The workforce is primarily concentrated in North America, and the average salary is $102,730.
OrthoPediatrics to Participate in the Canaccord Genuity 46th Annual Growth Conference
OrthoPediatrics Corp. (Nasdaq: KIDS) announced that its President & CEO, Dave Bailey, and COO & CFO, Fred Hite, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. An audio webcast and replay of the event will be available on the company's investor relations website. OrthoPediatrics focuses exclusively on pediatric orthopedics, offering over 90 systems for trauma and deformity, scoliosis, and sports medicine.
OrthoPediatrics to Participate in the Canaccord Genuity 46th Annual Growth Conference
OrthoPediatrics Corp. (Nasdaq: KIDS) announced its President & CEO, Dave Bailey, and COO & CFO, Fred Hite, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 9:00 am ET. An audio webcast and replay of the discussion will be available on the company's investor relations website. OrthoPediatrics focuses exclusively on pediatric orthopedics, offering a comprehensive product range across trauma, deformity, scoliosis, and sports medicine.
OrthoPediatrics to Join Canaccord Conference Aug. 12 | KIDS Stock News
OrthoPediatrics (Nasdaq: KIDS) announced that its President & CEO, Dave Bailey, and COO & CFO, Fred Hite, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026, at 9:00 a.m. ET. An audio webcast of the session will be available on the company's investor relations website, with a replay accessible afterwards. Historical data suggests conference participation notices have been followed by negative short-term stock reactions, while substantive product or earnings news has led to positive reactions.
